EASD 2017: inTandem3: More Patients With Type 1 Diabetes Who Received Sotagliflozin + Insulin Achieved HbA1C <7% vs Placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.